Clinical Trial Update: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating the combination of ibrutinib, a CD20 antibody, and venetoclax in patients with untreated mantle …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CD20 antibody
• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING